Detailed explanation of the contents and medication guide of Rubitidine/Rubicatin (Zanbiga)

Lurbinectedin (Lurbinectedin, trade name: rubicatin) is a new type of anti-cancer targeted drug, mainly used to treat small cell lung cancer (SCLC) and some other solid tumors. Its mechanism of action is mainly by inhibiting the activity of transcription factors in tumor cells, thereby interfering with the DNA repair and replication process of cancer cells, leading to cell apoptosis. This mechanism is different from traditional chemotherapy drugs, allowing rubitidine to show better efficacy in the treatment of refractory or recurrent cancers, especially for patients who have failed platinum-based chemotherapy in the past. According to the latest clinical research data, the overall response rate (ORR) of rubitidine monotherapy is about 30%, and it can maintain a longer progression-free survival (PFS) in some patients.

In terms of usage and dosage, rubitidine is usually administered by intravenous infusion. According to the drug instructions, the recommended dose is once every 21 days, the dose is 3.2 mg/m², and the infusion time is generally 1 hour. Before administration, the patient's liver and kidney function and hematological indicators should be assessed to ensure that the neutrophil count, platelet count and hemoglobin level are within a safe range. If the patient has abnormal liver function, the dose should be adjusted based on serum aminotransferase and bilirubin levels, and administration should be delayed if necessary. In addition, patients need to maintain a good hydration status during the medication, and monitor cardiac function, liver and kidney function, and blood picture changes in order to detect potential adverse reactions in a timely manner.

The adverse reactions of rubitidine mainly include hematological toxicity and non-hematological toxicity. The main hematological adverse reactions are neutropenia, anemia and thrombocytopenia, and some patients may be at risk of serious infection. Therefore, blood routine should be monitored regularly during treatment, and growth factors should be used or dosage adjusted according to the situation. Non-hematological adverse reactions mainly include fatigue, nausea, vomiting, loss of appetite, and increased liver function indicators. For patients who experience severe or persistent discomfort, the drug should be discontinued or the dose should be adjusted in a timely manner, and symptomatic and supportive treatment should be taken. In addition, the drug instructions specifically emphasize the restrictions on use for pregnant women, lactating women and patients with severe liver function abnormalities, and they need to strictly follow medical instructions.

In terms of patient education and medication management, multiple aspects of care and monitoring should be paid attention to during treatment with rubitidine. Patients need to clearly understand the importance of each infusion time, treatment interval and dose, and are not allowed to change the dosage regimen on their own. In terms of lifestyle, you should maintain good nutrition and work schedule to avoid the risk of infection, and pay attention to drug interactions. For example, useCYP3A4When used as inhibitors or inducers, the dose of rubitidine needs to be adjusted to avoid reduced efficacy or increased toxicity. In addition, when patients develop fever, signs of infection or severe discomfort, they should contact their attending physician immediately and adjust the dosage or suspend treatment if necessary. Taken together, as a new anti-cancer drug, rubitin's unique mechanism of action and relatively clear medication guidelines make it an important choice in the treatment of small cell lung cancer and some solid tumors. However, it must be carried out under the guidance of professional doctors and strictly follow the principles of individualized treatment to ensure a balance between safety and efficacy.

Reference materials:https://www.drugs.com/